2410 Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
TYK Medicines, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$22.10 |
| 52 Week High | HK$24.20 |
| 52 Week Low | HK$12.86 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 61.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2410 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 36.8% | 1.1% | 2.1% |
| 1Y | n/a | -28.2% | 3.4% |
Return vs Industry: Insufficient data to determine how 2410 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2410 performed against the Hong Kong Market.
Price Volatility
| 2410 volatility | |
|---|---|
| 2410 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in HK Market | 13.1% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 2410's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2410's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Yusheng Wu | www.tykmedicines.com |
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including breast cancer and prostate cancer; TY-2136b, an oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor for the treatment of solid tumors; TY-2699a, a selective CDK7 inhibitor for the treatment of advanced/metastatic solid tumors; and TY-0540, a selective CDK2/4/6 inhibitor to treat advanced/metastatic solid tumors.
TYK Medicines, Inc Fundamentals Summary
| 2410 fundamental statistics | |
|---|---|
| Market cap | HK$8.20b |
| Earnings (TTM) | -HK$445.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-18.4x
P/E RatioIs 2410 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2410 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥406.94m |
| Earnings | -CN¥406.94m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -8.6% |
How did 2410 perform over the long term?
See historical performance and comparison